Триттико

Quick links to important sections

Триттико

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Триттико

What is Триттико? (Overview)

Property Description
Active ingredient Trazodone Hydrochloride
Form Oral tablet (immediate and extended-release)
Pharmacological class Serotonin Antagonist and Reuptake Inhibitor (SARI)
General use Restoration of balanced mood states; relief of depressive illness
Origin Synthetic triazolopyridine derivative

What Type of Medicine is Триттико and What is its Composition?

Триттико is an antidepressant medication whose active substance is Trazodone Hydrochloride, a synthetic compound chemically classified as a triazolopyridine derivative. This medication belongs to the Serotonin Antagonist and Reuptake Inhibitor (SARI) pharmacological class, a category that is clinically recognized for its unique mechanism of action compared to older agents like tricyclic antidepressants.

The formulation is a single-ingredient product administered via the oral route, typically supplied as a film-coated oral tablet. Trazodone is often categorized as a multifunctional drug due to its complex profile. A key feature of the formulation is its availability in both standard immediate-release and specialized extended-release forms. This confirms the medication is specifically designed to accommodate different therapeutic needs, offering flexibility for sustained or immediate action.


How Does Триттико's Unique Class Define Its General Purpose?

The medicine's primary general purpose is to restore balanced mood states and improve emotional stability, establishing it as a core treatment within the domain of depressive illness. Its classification as a Serotonin Antagonist and Reuptake Inhibitor indicates it works by modulating the activity of chemical messengers in the brain.

The SARI mechanism ensures the drug's action by combining the effects of blocking specific receptors with inhibiting serotonin reuptake. By adjusting this chemical balance and promoting a calming influence, the medicine helps to relieve the emotional distress and persistent low mood associated with the condition. This dual action provides a high-level therapeutic benefit that includes addressing co-occurring symptoms, such as associated sleep disturbances, making it particularly suitable for patients whose depression involves significant insomnia.

Regulatory References

  1. NIH StatPearls Trazodone Review
  2. MedlinePlus Drug Information

What side effects are possible with Триттико?

Possible Side Effects and Safety Information

The safety profile of Trazodone (Triticco) is formally documented in government regulatory materials, categorizing known adverse reactions by frequency of occurrence and System-Organ-Class (SOC).

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions (ge 1/100 to <1/10) include drowsiness/sedation, dizziness, headache, dry mouth, and nausea.

Classification Examples of Reactions
Very Common (ge 1/10) Drowsiness, fatigue, dry mouth, dizziness, headache
Common Nausea, vomiting, constipation, orthostatic hypotension, blurred vision

Serious Adverse Reactions and Key Safety Concerns

Certain rare but clinically significant risks are highlighted in regulatory labeling:

  • Priapism: A prolonged and painful erection that requires immediate medical attention.
  • Serotonin Syndrome: A potentially life-threatening reaction, especially when Trazodone is combined with other serotonergic medications.
  • Hepatotoxicity: Rare but documented severe hepatic disorders, including jaundice.
  • Suicidal Thoughts and Behaviors: Risk is increased in children, adolescents, and young adults, particularly at the start of treatment or following dose adjustments.

Population-Specific Safety Statements

Official documents advise specific caution for certain groups:

  • Older Adults: Increased susceptibility to adverse reactions, particularly orthostatic hypotension (dizziness upon standing) and hyponatraemia (low sodium levels).
  • Pregnancy/Lactation: Use during pregnancy should be avoided unless clearly necessary. Neonates exposed during the third trimester should be monitored for withdrawal symptoms.

Regulatory Restrictions: Trazodone is typically contraindicated immediately following a myocardial infarction and in cases of acute alcohol or hypnotic intoxication. Patients should be warned about impaired ability to drive or operate machinery due to the risk of sedation.

Overdose and Emergency Response

The official regulatory profile for Trazodone overexposure defines it as a medical emergency due to the risk of severe systemic compromise.

Documented Overdose Signs

Element Regulatory Statement
Common Manifestations Symptoms documented in regulatory sources include somnolence, dizziness, vomiting, headache, and lack of coordination.
Physiological Systems Affected Severe effects involve the Central Nervous System (CNS) and Cardiovascular System, with documented risks of seizures, coma, respiratory arrest, and cardiac arrest.
Complicating Factors The severity of overdose is markedly increased when the drug is co-ingested with other CNS depressants, alcohol, or other serotonergic agents, which may precipitate Serotonin Syndrome.
Population Notes Risk of serious adverse effects is heightened in the elderly and in individuals with pre-existing cardiac, hepatic, or renal dysfunction.

Required Emergency Action

Regulatory agencies mandate that any suspected overdose requires that the individual seek immediate medical attention. This action is justified by the explicitly documented potential for life-threatening events such as Torsade de Pointes, ventricular tachycardia, and cardiac conduction abnormalities.

No specific antidote is known for Trazodone overexposure. Management is therefore limited to symptomatic and supportive treatment, including the potential use of activated charcoal and continuous ECG monitoring in a hospital setting, as specified in the official prescribing information.

Therapeutic Uses of Триттико

The medicine is relevant for conditions characterized by periods of heightened symptoms, primarily focusing on the symptomatic management of Major Depressive Disorder (MDD) in relevant patient groups. This medicine is used to treat depression. The therapeutic support offered may assist with easing the symptom load across key domains, including emotional distress, anxiety, and neurovegetative sleep disruption (insomnia).

The medicine is commonly used for managing symptoms that interfere with daily functioning, such as persistent low mood, nervousness, restlessness, and difficulty sleeping. It is relevant in situations involving distressing symptoms that may lead to temporary functional strain.

“This medication is applied in clinical settings that involve acute or unstable symptom patterns, offering supportive relief when symptoms become temporarily overwhelming.”

By addressing these clusters, the support provided may assist with maintaining a sense of stability when symptoms are more noticeable, contributing to improved comfort during symptomatic periods.


Quick Fact: Relief for Co-occurring Insomnia

Trazodone is often applied in scenarios where additional management of sleep disruption is required, particularly when difficulty falling asleep or nighttime awakenings complicate the underlying mood disorder.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official eligibility profile for Trazodone (Trazodone Hydrochloride) is defined by regulatory authorities based on age, acute health status, and pre-existing conditions. Use is formally established for adults (18 years and older) for the authorized indication.

Populations for Whom Use is Contraindicated

The medicine is formally prohibited in specific populations, often termed absolute contraindications in regulatory labeling:

  • Patients with documented hypersensitivity or allergic reaction to Trazodone or any ingredient in the formulation.
  • Individuals taking, or having stopped taking within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI).
  • Patients in the initial recovery phase following a myocardial infarction (heart attack).
  • Individuals during acute intoxication with alcohol or hypnotics.

Eligibility Constraints by Age and Condition

Population Group Regulatory Status / Restriction
Children and Adolescents (< 18 years) Not recommended (EU/UK labeling); Safety and efficacy have not been established (US labeling).
Older Adults (Geriatric) Use requires caution due to increased risk of orthostatic hypotension and hyponatremia.
Hepatic or Renal Impairment Use with caution, particularly if impairment is severe. Monitoring may be required.
Cardiac Disease Use requires particular caution and close monitoring for patients with pre-existing conditions like angina, conduction disorders, or long QT syndrome.

Pregnancy and Lactation: Regulatory data state that safety is not established in human pregnancy, and use should be considered only when the potential benefit justifies the potential risk. Trazodone passes into breast milk, and the decision to continue or discontinue treatment during lactation must weigh the drug's importance to the mother.

What should I know about interactions with other medicines?

The official regulatory profile for Trazodone Hydrochloride is structured around pharmacokinetic and pharmacodynamic interactions.

Contraindicated and Pharmacodynamic Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the significant risk of Serotonin Syndrome. A mandatory 14-day washout period must separate the use of Trazodone and any MAOI. Use with other serotonergic agents (e.g., SSRIs, Triptans, St. John's Wort) similarly increases this risk. Trazodone may intensify the effects of CNS depressants (including alcohol), which are restricted due to enhanced sedation.

Pharmacokinetic and Exposure Constraints

Trazodone's metabolism is predominantly mediated by the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors (e.g., Ritonavir) substantially increases Trazodone plasma concentration, requiring specific caution. Conversely, strong CYP3A4 inducers (e.g., Carbamazepine) significantly decrease Trazodone exposure. Caution is advised for patients with severe hepatic impairment due to the potential for increased exposure in interaction scenarios.

Additive Organ-Specific Risk

Other documented interactions involve an increased risk of abnormal bleeding with co-administration of antiplatelet agents or anticoagulants (e.g., Warfarin, NSAIDs). Furthermore, caution is noted with drugs that prolong the QT/QTc interval due to the potential for cardiac arrhythmia risk.

Mechanism of Action

The mechanism of Триттико (Trazodone) is defined by its action as a multifunctional Serotonin Antagonist and Reuptake Inhibitor (SARI), a profile that selectively modulates several key neurotransmitter systems simultaneously.

Targeted Serotonergic and Arousal System Blockade

This domain covers the drug's rapid, high-affinity antagonism of the 5- HT2 A, Histamine H1, and Alpha-1 Adrenergic (alpha1) receptors. Blocking the H1 and alpha1 receptors immediately attenuates central arousal signaling, while 5- HT2 A blockade results in the modulation of serotonin signaling within circuits governing monoamine signal transduction.

Functional Serotonin Rebalancing

This mechanism involves the drug's dual action on the serotonergic system: 5- HT2 A antagonism coupled with a weak inhibition of the Serotonin Transporter ( SERT). This synergy influences pathways of monoamine signal transduction, resulting in gradual increases in functional synaptic serotonin availability.

Concentration-Dependent Mechanistic Profile

The drug exhibits differential binding affinity across its targets, creating a concentration-dependent mechanistic profile. High-affinity antagonism ( H1, alpha1) dominates at low concentrations, driving the rapid initial physiological effects, whereas the lower-affinity SERT inhibition and long-term 5- HT2 A effects determine the comprehensive expression of the drug's pharmacodynamic effects.

Dosage and Administration Information

How to Use Триттико: Official Administration Guidelines

Administration of Trazodone Hydrochloride, the active ingredient in Trittico, is defined by specific procedural instructions governing route, dosage, frequency, and duration.


Administration Scope

Field Official Instruction
Route of administration The approved administration route is oral (by mouth).
Dosing schedule Treatment typically begins at 150 mg per day in divided doses. The dosage may be increased by 50 mg per day every three to four days to achieve the required level. The maximum recommended dose for outpatients is 400 mg per day in divided doses.
Timing in relation to meals Immediate-Release (IR) tablets are generally taken shortly after a meal or a light snack. Extended-Release (ER) tablets are typically taken on an empty stomach at the same time each day, preferably at bedtime.
Age-group administration For Older Adults, the initial dose is often reduced. Use in pediatric patients (under 18) is not recommended due to insufficient data on safety and efficacy.
Special procedural conditions The major portion of the total daily dose is often given at bedtime. Treatment must be gradually reduced (tapered) upon discontinuation and should not be stopped abruptly. Tablets must not be crushed or chewed.

Resulting Procedural Structure

The administration method is strictly Oral and adheres to a Daily frequency pattern. The protocol involves initiating treatment with a low dose and adjusting it gradually over several days. The administration is constrained by specific rules regarding food dependency for the IR formulation and the time of day for the major dose, usually at night. This framework dictates the required sequence for beginning, adjusting, and concluding the use of the medicine, adhering to standards for proper administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Триттико

Evidence for use in Major Depressive Disorder (MDD)

Research related to the medicine has focused on conditions involving periods of heightened symptoms, specifically Major Depressive Disorder (MDD). The evidence is mainly derived from short-term Randomized Controlled Trials (RCTs) where the medicine was evaluated against an inactive substance (placebo). Studies also compared outcomes against other established antidepressant classes.

In these studies, researchers monitored outcomes related to symptom intensity or variability, tracking changes using standardized rating scales for depression severity. The research highlights changes measured during the study period in the severity of core depressive symptoms. Findings describe group patterns observed in these studies where outcomes were measured against other agents. The existing evidence includes certain limitations, as more comparative evidence is lacking against some of the newest antidepressant medications.


Evidence for use in Co-occurring Insomnia and Sleep Disruption

Research has consistently explored outcomes related to sleep disruption where the medicine was administered, especially when it is associated with acute or disruptive episodes of depression. The outcomes monitored in these studies included both subjective reports (how patients perceived their sleep) and objective measurements, such as the total time spent sleeping. Studies monitored outcomes related to sleep quality and sleep continuity, and findings describe patterns observed during these study periods. The evidence contributes to understanding symptom patterns related to sleep difficulties across short durations.


Research Gaps and Areas of Uncertainty

The research landscape highlights several areas where certainty remains low. Evidence quality varies across studies, particularly those focused solely on sleep, which may be small or lack objective measurements. While the medicine was studied for this context decades ago, contemporary comparative evidence is lacking for many aspects. Long-term effects are not fully established or well-characterized, particularly regarding the maintenance of symptom relief over extended periods.

Key Studies & References

  1. TRAZODONE HYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1981 - Full Prescribing Information
  2. The efficacy and safety of trazodone for sleep problems in depressive patients: a GRADE-assessed systematic review and meta-analysis of clinical trials
  3. Trazodone in the Management of Major Depression Among Elderly Patients with Dementia: A Narrative Review and Clinical Insights

Frequently Asked Questions (FAQ)

Common questions about Триттико (FAQ)


Q: Is Триттико considered an antidepressant or a sleep aid?

A: Триттико's official indication, according to regulatory documents, is for the treatment of Major Depressive Disorder. However, its known side effect of drowsiness or sedation is often leveraged by healthcare providers to address the associated sleep disturbances and insomnia in patients with depression. It is chemically classified as an antidepressant.

Q: How does Триттико chemically affect the brain?

A: Триттико (trazodone) belongs to a class of medicines called Serotonin Antagonists and Reuptake Inhibitors (SARI). Official information states that this means it works by blocking certain chemical receptors in the brain and also weakly prevents the reuptake of serotonin. This dual action modulates the balance of chemical messengers in the brain to help restore a more stable mood state.

Q: Can Триттико help with anxiety as well as depression?

A: Official information indicates that the primary use is for Major Depressive Disorder. However, regulatory documents mention that clinical studies have noted a reduction in symptoms like anxiety, tension, and other somatic symptoms (physical discomfort) that are often associated with the depressive illness.

Q: Can Триттико cause stomach or digestive issues?

A: Yes, commonly reported adverse reactions listed in the official product information include gastrointestinal issues such as nausea, vomiting, and constipation. Patients are generally advised to report any persistent adverse effects to their healthcare provider.

Q: How long does Триттико stay in your system after stopping it?

A: Trazodone has a relatively short half-life, meaning the amount of medicine in the body significantly decreases after the last dose. Generally, the concentration of the drug is substantially reduced and eliminated from the body within 1 to 3 days, though this timeframe can vary widely based on individual metabolism.

Q: Is there a risk of dependency or addiction with Триттико?

A: Official labeling does not classify the medicine as having a high risk of addiction. However, the drug is associated with discontinuation symptoms if it is stopped abruptly. For this reason, official administration guidelines recommend that the dosage be gradually reduced (tapered) when ending treatment to minimize such effects.

Q: Why do some people take Триттико at a low dose?

A: The effects of the medicine are concentration-dependent. At lower doses, the effects that cause sedation and sleepiness tend to be more prominent due to the drug’s high-affinity receptor blockade. The full antidepressant effect generally requires a higher concentration of the drug.

Q: Are there long-term effects of taking Триттико?

A: Research on the efficacy of Trazodone has primarily focused on short-term treatment (several weeks). Official information indicates that the effects of the drug for maintenance treatment (long-term use) for major depressive disorder have not been fully established or evaluated in extensive clinical trials.

Q: Does Триттико affect blood pressure?

A: Yes, the medication can affect blood pressure, particularly upon changing position. A common adverse reaction noted in the label is orthostatic hypotension (a sudden drop in blood pressure when moving to a standing position), which can cause dizziness and, in some cases, fainting.

Q: Is it normal for Триттико to make me dizzy when I stand up?

A: Yes, this is a documented side effect. The official label notes the risk of orthostatic hypotension, which is commonly experienced as dizziness or lightheadedness when rising quickly. The risk of this side effect is noted to be increased in certain populations, such as older adults.

Q: Can Триттико be taken with other mood stabilizers?

A: Official product information warns about using Trazodone with any other serotonergic agents (medicines that affect serotonin levels) due to the increased risk of a serious condition called Serotonin Syndrome. It is important that healthcare providers are informed of all current medications, including mood stabilizers, to assess this risk.

Q: What clinical research supports the use of Триттико for insomnia?

A: The drug is officially approved for Major Depressive Disorder. Research supporting its use for sleep is primarily linked to its effect on treating depression, where studies have shown it can improve sleep disturbances and objective sleep outcomes associated with the condition.

Q: How should Триттико be stored?

A: Official regulatory requirements state that the medicine should be stored at controlled room temperature, typically between 20 C to 25 C. It must be kept in the original container, tightly closed, and protected from moisture and excess heat.

Q: What are the signs of an allergic reaction to Триттико?

A: Trazodone is contraindicated for people with a known hypersensitivity to the active ingredient. Signs of a severe allergic reaction typically include swelling, hives, skin rashes, or difficulty breathing. These signs are considered serious adverse reactions and warrant prompt attention.

Q: What is the difference between Триттико and trazodone?

A: Триттико is the brand name, or proprietary name, for the medicine. Trazodone hydrochloride is the generic name for the active chemical ingredient in the drug. Both names refer to the same therapeutic substance.

Q: Is Триттико generally considered safe for people with glaucoma?

A: Official labeling notes that the medicine can, in rare cases, trigger an acute angle-closure glaucoma attack. Regulatory documents state that patients with pre-existing angle closure should be closely monitored and may require evaluation during treatment.

Q: Are there common vitamins or supplements that interact with Триттико?

A: The label specifically notes that co-administration with the herbal supplement St. John's Wort can increase the risk of Serotonin Syndrome due to its effect on serotonin levels. Regulatory guidelines emphasize the need to inform healthcare providers about all supplements being taken.

Q: Does Триттико affect male or female libido?

A: Changes in sexual function, including libido, are sometimes reported with medications in this class. Official labeling for Trazodone lists Priapism (a prolonged, painful erection) as a serious, though rare, side effect.

Q: What happens if I take Триттико on an empty stomach?

A: Official instructions advise taking the immediate-release (IR) tablet shortly after a meal or light snack. Taking this formulation on an empty stomach may cause the body to absorb the medicine faster, which could potentially lead to a greater risk of adverse effects like dizziness or lightheadedness.

Q: Is it possible for Триттико to increase anxiety initially?

A: Official labeling includes warnings to monitor patients for symptoms such as agitation and anxiety particularly when treatment is initiated or after a dose adjustment. This monitoring is a standard part of patient care.

Q: What evidence exists about Триттико's effectiveness in long-term treatment?

A: The effectiveness of the medication has been established in short-term clinical trials typically lasting several weeks. Official information states that the efficacy for use beyond these initial short periods is not fully established.

Q: Does Триттико have a generic equivalent?

A: Yes, the active ingredient trazodone hydrochloride is available as a generic medicine in various dosage forms and strengths. The generic equivalent is generally considered therapeutically equivalent to the brand name product.

Q: What are the possible interactions between Триттико and grapefruit juice?

A: Trazodone is broken down by the CYP3A4 enzyme. Since grapefruit and grapefruit juice can inhibit this enzyme, consumption may increase the concentration of the medicine in the blood, potentially raising the risk of adverse effects.

Q: Is Триттико considered a tricyclic antidepressant?

A: No, Триттико is not classified as a tricyclic antidepressant (TCA). Official regulatory documents classify it as a Serotonin Antagonist and Reuptake Inhibitor (SARI), and chemically, it is a triazolopyridine derivative.

Q: What should I do if I experience unexpected side effects from Триттико?

A: Patients are advised to report any unexpected, persistent, or bothersome adverse reactions to their prescribing healthcare provider. Serious reactions, such as a prolonged erection (Priapism) or signs of Serotonin Syndrome, are highlighted in the official warnings as requiring prompt professional attention.

Q: Does Триттико show up on standard drug tests?

A: Trazodone itself is not typically screened for on standard drug abuse panels. However, a major metabolite of Trazodone, m-CPP, has been known to cause false positive results for substances like amphetamines on some initial urine drug screens.

Q: What happens if you miss a dose of Триттико?

A: Official administration guidelines focus on scheduled dosing. If a dose is missed, patients should follow the specific instructions provided by their pharmacist or healthcare provider to ensure proper timing and to avoid accidentally taking two doses too closely together.

Q: What should I avoid eating or drinking when taking Триттико?

A: Regulatory documents state that patients should avoid alcohol, as it can dangerously increase the sedating effects of the medication. Additionally, the official label warns about potential interactions with grapefruit or grapefruit juice due to its effect on the drug's metabolism.

Q: Why do doctors often prescribe a lower dose of Триттико for sleep than for depression?

A: This approach is based on the drug's concentration-dependent mechanism. The effects that help with sleep (blocking specific receptors) can occur at lower concentrations, while the full therapeutic action required for depression (inhibiting serotonin reuptake) occurs at higher concentrations.

How should Триттико be stored and disposed of?

Official Storage Requirements

Storage Factor Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze or store above 25 C.
Protection Keep away from moisture, excess heat, and direct light.
Container Store in the original container and ensure the cap or closure is tightly closed.

Stability and Safety

To ensure product stability, the medication must not be used after the expiry date printed on the packaging. As a mandatory safety requirement, always store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Trazodone tablets must not be disposed of in household trash or flushed down the toilet, as this violates pharmaceutical waste protocols. Consult a pharmacist or utilize a drug take-back program for the proper disposal of any unused or outdated medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Триттико found in:

A-Z Index: